Inozyme Pharma Appoints Erik Harris to Board for Rare Disease Therapy Expansion

Inozyme Pharma, a biopharmaceutical company in the clinical stage of developing treatments for rare diseases that impact bone health and blood vessel function, announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings over two decades of commercial expertise in the biopharma sector. His leadership experience in launching therapies for rare diseases is expected to significantly benefit Inozyme as the company prepares to transition into a commercial-stage enterprise.

Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme, expressed enthusiasm for Harris joining the board, emphasizing his proven success in driving commercial strategies for rare disease treatments. Treco noted that Harris' deep commercial insights would be particularly valuable as Inozyme moves its lead program, INZ-701, through late-stage development and prepares for its eventual market launch.

Erik Harris also commented on his new role, expressing excitement about collaborating with Inozyme’s team. He highlighted the potential of INZ-701 as a transformative therapy for a range of rare diseases affecting bone health and blood vessel function and expressed his commitment to helping Inozyme deliver this important treatment to patients in need.

Before his current role at Ultragenyx, Harris held leadership positions at Crescendo Bioscience, Intermune, Genentech, Elan Pharmaceuticals, and Bristol-Myers Squibb. He also serves on the Board of Directors at Denali Therapeutics. Earlier in his career, Harris served as a Lieutenant Commander in Naval Aviation and a Congressional Fellow for the U.S. Navy. He holds an M.B.A. from the Wharton School of Business and a B.S. from the U.S. Naval Academy.